Autumn Leaves

Fall 2014 Cancer Conferences to Watch Out for

The leaves are turning and the weather is getting cooler in many parts of the country, so what are some of the cancer conferences to watch out for before the year end? On Biotech Strategy Blog we’ll be writing about four major medical and scientific meetings including SITC 2014 in Maryland, EORTC-NCI-AACR Molecular Targets in […]

Continue Reading
ESMO 2014 Congress - Madrid, Spain

ESMO 2014 Conference Coverage

The ESMO 2014 Congress takes place in Madrid at the end of September (Sept 26 -30) and we are already planning our conference coverage. Sadly, the ESMO and ECCO annual meetings have moved in a negative direction with this year’s meeting excluding nurses, patient advocates and media from the exhibit hall and industry satellite symposia, […]

Continue Reading
Greenwich London

Do you have a fast to market oncology new products strategy?

Pharma marketing strategy is a key part of every consulting project we do, whether it be a landscape report, thought leader market research or identifying target opportunities for oncology and hematology new products. We are constantly on the look out for fast-to-market strategies in market segments with high unmet medical need where emerging science and […]

Continue Reading
Cellectis CSO Phillippe Duchateau and CEO André Choulika

Who will win CAR-T cell immunotherapy race to market?

Chimeric Antigen Receptor T cell immunotherapy (known as CAR-T or more colloquially as CART)  has been in the news recently. Novartis/UPenn announced they received Breakthrough Therapy Designation (BTD) from the US Food & Drug Administration (FDA) for their CTL019 product in relapsed/refractory acute lymphocytic leukemia (ALL). Dr Stephen Grupp from The Children’s Hospital of Philadelphia […]

Continue Reading
Dr Sally Church ASCO 2014

ASCO 2014 Immuno-Oncology Review

Immuno-oncology was one of the hot topics in cancer drug development at ASCO 2014. Readers may recall my ASCO 2013 preview video that highlighted the significance of data for immune checkpoint inhibitors – this was when anti PD-1, PD-L1 compounds were generally not on many people’s radar. One thing we work hard at is picking […]

Continue Reading
Dr Janne AZD9291 Interview ASCO 2014

AstraZeneca AZD9291 shows lung cancer promise at ASCO 2014

The annual pilgrimage for cancer drug development professionals to ASCO (the annual meeting of the American Society of Clinical Oncology) in Chicago is over, and now we have to digest the tsunami of data such meetings create. The challenge with conferences such as these is not obtaining access to data – most of it is […]

Continue Reading
California Flag

2014 is the year of Immuno-Oncology

One of the hot topic of conversation amongst the VCs at the JP Morgan Healthcare conference in San Francisco this past week was the field of immuno-oncology. We have already seen significant excitement in anti-PD1/PD-L1 drugs and their early promise in melanoma, renal and lung cancers. Taking a more strategic view, however, the question is […]

Continue Reading
Picton Reading Room Liverpool

Oncology New Product Executive Coaching

In response to numerous client requests, one of the services we now offer is 1:1 executive coaching on Oncology New Product Development. The aim of this program is to facilitate a greater understanding of emerging cancer targets through a series of custom case studies and 1:1 coaching sessions.

Continue Reading